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Background: To observe the treatment effects of different dialysis modalities on pruritus in elderly
uremic patients.
Methods: After screening, 67 elderly dialysis patients were selected, including 25 hemodialysis (HD)
patients, 20 HD combined with hemodiaﬁltration (HD þ HDF) patients, and 22 peritoneal dialysis (PD)
patients. The b2-microglobulin (b2-MG) and intact parathyroid hormone (iPTH) levels were measured
before the initial dialysis, and 8 and 12 weeks after the dialysis. During these periods, cutaneous pruritus
scores were documented and the remission rate of itching was calculated.
Results: There were signiﬁcant differences in the plasma b2-MG and iPTH levels at 8 and 12 weeks after
the initial dialysis in the HDF and PD groups (all p < 0.05). There were also signiﬁcant differences in
cutaneous pruritus scores (all p < 0.01) in the HDF and PD groups, but the scores showed no signiﬁcant
difference in the HD group (all p > 0.05). After 12 weeks of treatment, the pruritus remission rates in the
PD, HDF, and HD groups were 68.18%, 60.00%, and 24.00%, respectively.
Conclusion: PD and HDF can clear b2-MG and iPTH and provide relief from cutaneous pruritus efﬁciently
in elderly uremic patients.
Copyright © 2014, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
The physiology of elderly uremic patients is different from that
of the general population, and the physiologic condition of this
group is complex with various related complications; for example,
refractory pruritus is one of the most common complications and
severely affects the patient's quality of life and long-term
survival1e3. Previous studies have shown that the accumulation
of middle-molecule toxins such as b2-microglobulin (b2-MG) and
intact parathyroid hormone (iPTH) is an important factor that can
cause complications such as severe uremic pruritus (UP) and sleep
disorders4,5. Hemodialysis (HD), especially high-ﬂux HD, is
currently the most commonly used blood puriﬁcation method
worldwide, but in China and other developing countries, due to the
low level of economic development, low-ﬂux dialysis is the mainre that they have no conﬂicts
ent of Nephrology, Second
iang Road, Jinchang District,
r.
tric Emergency & Critical Care Memethod of extracorporeal blood puriﬁcation therapy; however, this
method can hardly remove the middle-molecule uremic toxins and
provide relief from UP6,7. By contrast, hemodiaﬁltration (HDF) can
remove middle-molecular and macromolecular substances
through diffusion and convection6. To compensate for the de-
ﬁciencies of HD, many Chinese hospitals are now using a combined
HD and HDF treatment approach (HDþ HDF). In addition, given the
gradual improvements in the Chinese medical insurance system
and the recent continued in-depth understanding of peritoneal
dialysis (PD), most uremic patients now prefer PD.
The purpose of this clinical study was to compare the capabil-
ities of HD, HD þ HDF, and PD in clearing middle-molecule toxins
and their effects on pruritus in elderly uremic patients.2. Materials and methods
2.1. Patients
After screening, 67 elderly patients (age  60 years) with UP
who began dialysis at the Dialysis Center in our hospital from May
2011 to May 2013 were included in this study, including 25 cases indicine. Published by Elsevier Taiwan LLC. All rights reserved.
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group. All patients met the diagnostic criteria for UP8. In addition,
none of the included patients had severe heart and liver diseases,
severe chronic diseases, or serious complicating infections. The
most common primary diseases were chronic glomerulonephritis,
diabetic nephropathy, and hypertensive nephropathy (Table 1).2.2. Methods
2.2.1. Basic treatment
The daily sodium intake of all patients was controlled at 2e3 g
and was adjusted according to the disease condition and the serum
sodium level. The phosphorus intake of the patients was less than
600e800mg/day, and the protein intake exceeded 1.2 g/kg/day and
included high-quality animal-based protein. The daily caloric
intake was 35e40 kcal/kg, and carbohydrates accounted for
60e65% of this value. Patients received intravenous erythropoietin
and oral iron therapy to maintain the hemoglobin levels at
110e120 g/L. Patients with serum iPTH levels greater than 300 ng/L
received oral calcitriol capsules (Rocaltrol; Roche, Mannheim,
Germany) at a daily dose of 0.25 mg since the start of dialysis; pa-
tients with hypertension were also treated with antihypertensive
drugs.2.2.2. Dialysis treatment
In the HD group, conventional HD was performed three times/
week. All patients used a hollow ﬁber dialyzer (DICEA-130G; Baxter
International, Inc., Deerﬁeld, IL, USA) for dialysis. The membrane
area of the dialyzer was 1.3 m2 and its ultraﬁltration coefﬁcient was
10 mL/h/mmHg. General heparin was used as the anticoagulant
(30e50 mg/session). The patients received bicarbonate dialysis
(calcium concentration in the dialysate, 1.5 mmol/L; dialysate ﬂow
rate, 500mL/minute; and dialysis blood ﬂow, 240e260 mL/minute;
the ultraﬁltration volume was based on the dry body weight). For
the HDF group, one HDF was performed every week (TS-1.6U
hemoﬁlter; Toray Medical Co., Shizuoka, Japan), based on two-
times-weekly conventional HD. The blood-ﬁltration replacement
volume after each session was diluted to 40e50 L. The duration of
each treatment session was 4 hours. In the PD group, continuous
ambulatory PD was performed on all patients. In brief, 2000 mL of
1.5% PD solution was left in the abdomen for 4 hours three times
daily, and 2000mL of 2.5% PD solutionwas left in the abdomen for 8
hours (overnight) one time daily. The PD solution and the duplex
system were produced by Baxter.2.2.3. Measurements of the b2-MG and iPTH levels
Changes in the levels of serum b2-MG and iPTH before dialysis
in patients were measured by the radioimmunoassay method. The
levels were againmeasured 8 and 12 weeks after the initial dialysis.
The kits used to detect b2-MG and iPTH were obtained from theTable 1
Etiology of the study population.
Etiology of ESRD PD group
(n ¼ 22)
HDF group
(n ¼ 20)
HD group
(n ¼ 25)
Chronic glomerulonephritis 12 10 11
Diabetic nephropathy 4 3 6
Hypertensive nephropathy 3 4 5
Adult polycystic kidney disease 0 0 2
Obstructive nephropathy 0 1 0
Gouty nephropathy 1 0 0
Unknown 2 2 1
ESRD ¼ end-stage renal disease; HD ¼ hemodialysis; HDF ¼ hemodiaﬁltration;
PD ¼ peritoneal dialysis.American BioSource Company (San Diego, CA, USA). Kt/V was
calculated in each group 8 and 12 weeks after the initial dialysis.
2.2.4. Pruritus scoring and treatment effect criteria
Pruritus was scored before the initial dialysis and also 8 and 12
weeks after the dialysis. The scoring was based on the severity,
distribution, frequency, and sleep disturbance associated with
pruritus, according to a previous report9.
The criteria for the treatment effects on pruritus were as fol-
lows: (1) cured, pruritus disappeared or only pigment changes were
observed; (2) signiﬁcantly effective, pruritus symptoms were
signiﬁcantly relieved and scratching was not necessary; (3) effec-
tive, pruritus symptoms were slightly relieved and scratching was
required to relieve the itching; and (4) ineffective, pruritus symp-
toms were not relieved or were even aggravated. The pruritus
remission rate was calculated as follows: remission rate ¼
(cured þ signiﬁcantly effective þ effective)/total number of cases.
2.3. Statistical analysis
Statistical analysis was performed with SPSS 17.0 software (SPSS
Inc., Chicago, IL, USA). The data were presented as
means ± standard deviations (x ± SD) and were analyzed with
analysis of variance (ANOVA). Comparisons between two groups
were performed with the t test. Comparative analyses of multiple
groups were performed with the single-factor ANOVA. Compari-
sons of factors before and after dialysis were performed with the
paired t test, and the count data were examined with the c2 test. If
the data were not normally distributed, then the Wilcoxon test was
used instead of the t test and the paired t test. We also used analysis
of covariance (ANCOVA) by adjusting blood iPTH levels to deter-
mine whether b2-MG level was the major determinant for pruritus
in this study. The signiﬁcance level for two-tailed alpha was set at
0.05. The study protocol was approved by the Ethics Committee of
our institution.
3. Results
3.1. Comparison of the clinical characteristics and Kt/V in each
group
Before the initial dialysis, a comparison of the clinical parame-
ters, including the patients' age, mean arterial pressure, creatinine,
albumin, and hemoglobin levels, and other variables revealed no
signiﬁcant differences (all p > 0.05). The Kt/V value of all patients in
the HD or HDF group was 1.4, whereas it was 1.7 in the PD group
patients; 8 or 12 weeks later, patients in all the three groups
received adequate dialysis. A comparison of the fasting glucose
level revealed no differences either before the initial dialysis or
after 12 weeks (both p > 0.05). Therewere also no differences in the
number of patients taking calcitriol and the dosages of calcitriol
intake (both p > 0.05; Table 2).
3.2. Serum b2-MG and iPTH level changes
Before the initial dialysis, the b2-MG and iPTH levels of the three
groups were all not signiﬁcantly different (all p > 0.05). When
compared with the levels before the initial dialysis, the b2-MG level
in the HD group changed from 16.25 ± 4.23 to 16.81 ± 4.31 mg/L
(t ¼ 0.435, p ¼ 0.668) after 8 weeks of dialysis and to
19.01 ± 4.03 mg/L (t ¼ 2.216, p ¼ 0.038) after 12 weeks; the iPTH
level changed from 458.87 ± 221.32 to 428.37 ± 298.13 ng/L
(t ¼ 0.411, p ¼ 0.685) after 8 weeks and to 498.25 ± 278.47 ng/L
(t¼0.554, p¼ 0.585) after 12weeks. In the HDF group, the b2-MG
level decreased from 17.78 ± 4.17 to 15.02 ± 3.89 mg/L (t ¼ 2.164,
Table 4
Comparison of the serum iPTH levels.
Group Number
of cases
Before the
initial dialysis
After 8 wk
of dialysis
After 12 wk
of dialysis
HD 25 458.87 ± 221.32 428.37 ± 298.13 498.25 ± 278.47
HDF 20 469.38 ± 198.47 340.21 ± 165.23* 298.36 ± 167.45*,**
PD 22 441.35 ± 178.63 298.13 ± 146.37** 252.68 ± 153.25**
Data are presented as x ± SD (ng/L).
Compared with the same group before dialysis, *p < 0.05, **p < 0.01, *,**p < 0.01; 12
weeks after the initial dialysis, compared with the HD group, *p < 0.01, *,**p < 0.05.
HD ¼ hemodialysis; HDF ¼ hemodiaﬁltration; PD ¼ peritoneal dialysis;
iPTH ¼ intact parathyroid hormone; SD ¼ standard deviation.
Table 2
Clinical characteristics and Kt/V of the three groups.
Clinical parameters PD group
(n ¼ 22)
HDF group
(n ¼ 20)
HD group
(n ¼ 25)
p
Age (y) 68.05 ± 10.48 69.16 ± 9.52 67.22 ± 7.85 0.785
Male [% (n/N)] 36.36 (8/22) 45.00 (9/20) 52.00 (13/25) 0.561
Hb (g/L) 109.45 ± 7.21 105.72 ± 6.47 108.51 ± 17.98 0.597
Alb (g/dL) 33.98 ± 5.04 37.34 ± 7.08 36.21 ± 6.47 0.210
MAP (mmHg) 108.05 ± 8.47 106.15 ± 7.03 105.23 ± 6.54 0.420
BMI (kg/m2) 23.32 ± 1.46 22.65 ± 3.69 21.58 ± 6.03 0.378
Scr (mmol/L) 959.12 ± 256.47 1007.31 ± 217.37 987.15 ± 195.23 0.781
P3þ (mg/dL) 6.31 ± 1.51 5.62 ± 1.63 6.08 ± 1.12 0.285
DM [% (n/N)] 18.18 (4/22) 15.00 (3/20) 24.00 (6/25) 0.738
EF (%) 68.17 ± 9.22 69.13 ± 10.52 64.83 ± 8.90 0.279
SI (mmol/L) 12.63 ± 4.01 12.21 ± 5.11 12.93 ± 4.78 0.875
HR (time/min) 76.89 ± 17.78 72.08 ± 21.18 79.45 ± 20.37 0.463
nPCR (g/kg/d) 0.86 ± 0.23 0.81 ± 0.12 0.89 ± 0.21 0.397
CRP (mg/L)a 4.6 (2.9e9.3) 5.3 (4.1e7.2) 4.8 (3.8e8.9) 0.511
Ca2þ (mg/dL) 8.31 ± 0.83 8.56 ± 0.93 8.47 ± 0.77 0.619
spKt/Vb e 1.47 ± 0.26 1.43 ± 0.33 0.662
spKt/Vc e 1.50 ± 0.46 1.45 ± 0.29 0.660
Kt/V ureab,d 1.84 ± 0.83 e e e
Kt/V ureac,d 1.78 ± 0.47 e e e
Vitamin D3 use (%) 59.09 (13/22) 50.00 (10/20) 56.00 (14/25) 0.835
Vitamin D3 dose
(mg/d)
0.25 0.25 0.25 e
Glu (mmol/L)e 5.85 ± 0.83 6.12 ± 1.06 5.56 ± 0.98 0.157
Glu (mmol/L)c 6.01 ± 1.35 5.81 ± 1.21 6.28 ± 1.62 0.540
Alb ¼ serum albumin; BMI ¼ body mass index (weight/height2); Ca2þ ¼ serum
calcium; CRP ¼ C-reactive protein; DM ¼ diabetes mellitus; EF ¼ ejection fraction;
Glu ¼ fasting glucose; Hb ¼ hemoglobin; HD ¼ hemodialysis;
HDF ¼ hemodiaﬁltration; HR ¼ heart rate; MAP ¼ mean arterial pressure;
nPCR ¼ normalized protein catabolic rate; P3þ ¼ serum phosphorus;
PD ¼ peritoneal dialysis; Scr ¼ serum creatinine; SI ¼ serum iron; spKt/V ¼ eLn(Re
0.008  T) þ (4e3.5  R)  UF/BW; Vitamin D3 ¼ calcitriol.
a Expressed as the median (interquartile range).
b Expressed as 8 weeks after the initial dialysis.
c Expressed as 12 weeks after the initial dialysis.
d Expressed as weekly Kt/V.
e Expressed as before the initial dialysis.
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p ¼ 0.009) after 12 weeks; the iPTH level decreased from
469.38 ± 198.47 to 340.21 ± 165.23 mg/L (t¼ 2.237, p¼ 0.038) after
8 weeks and to 298.36 ± 167.45 mg/L (t ¼ 2.945, p ¼ 0.008) after 12
weeks. In the PD group, the b2-MG level decreased from
18.25 ± 4.87 to 15.32 ± 4.06 mg/L (t ¼ 2.168, p ¼ 0.042) after 8
weeks and to 11.09 ± 3.57 mg/L (t ¼ 5.562, p ¼ 0.000) after 12
weeks; the iPTH level decreased from 441.35 ± 178.63 to
298.13 ± 146.37 mg/L (t ¼ 2.909, p ¼ 0.008) after 8 weeks and to
252.68 ± 153.25 mg/L (t¼ 3.760, p¼ 0.001) after 12 weeks. After 12
weeks, the b2-MG and iPTH levels in the HDF and PD groups were
both signiﬁcantly lower than that in the HD group (both p < 0.05;
Tables 3 and 4).
3.3. Comparison of the skin pruritus scores
Before the initial dialysis, the pruritus scores of the three groups
were not signiﬁcantly different (all p > 0.05). When compared withTable 3
Comparison of the serum b2-MG levels.
Group Number
of cases
Before the
initial dialysis
After 8 wk
of dialysis
After 12 wk
of dialysis
HD 25 16.25 ± 4.23 16.81 ± 4.31 19.01 ± 4.03
HDF 20 17.78 ± 4.17 15.02 ± 3.89* 14.04 ± 3.97**
PD 22 18.25 ± 4.87 15.32 ± 4.06* 11.09 ± 3.57**
Data are presented as x ± SD (mg/L).
Compared with the same group before the initial dialysis: *p < 0.05, **p < 0.01; 12
weeks after the initial dialysis, compared with the HD group, **p < 0.01.
HD ¼ hemodialysis; HDF ¼ hemodiaﬁltration; PD ¼ peritoneal dialysis; b2-
MG ¼ b2-microglobulin.the levels before the initial dialysis, the pruritus scores in the HD
group changed from 23.01 ± 3.58 to 21.95 ± 4.27 points (t ¼ 0.951,
p ¼ 0.351) after 8 weeks of dialysis and to 24.68 ± 4.39 points
(t ¼ 1.474, p ¼ 0.153) after 12 weeks. In the HDF group, the pru-
ritus scores decreased from 20.98 ± 4.02 to 15.08 ± 3.56 points
(t ¼ 4.914, p ¼ 0.000) after 8 weeks of dialysis and to 12.12 ± 2.98
points (t ¼ 7.918, p ¼ 0.000) after 12 weeks. In the PD group, the
pruritus scores reduced from 22.15 ± 4.98 to 14.38 ± 4.01 points
(t ¼ 5.700, p ¼ 0.000) after 8 weeks of dialysis and to 9.08 ± 3.55
points (t ¼ 10.024, p ¼ 0.000) after 12 weeks. After 12 weeks, the
pruritus scores in the HDF and PD groups were signiﬁcantly lower
than that in the HD group (both p < 0.01; Table 5). Meanwhile, we
used ANCOVA by adjusting the blood iPTH levels and found that b2-
MG and iPTH levels were independently associated with the
development of severe UP (p > 0.05).
3.4. Comparison of the effects of treatment on UP
After 12 weeks of treatment, the pruritus remission rates in the
PD group, HDF group, and HD group were 68.18% (15/22), 60% (12/
20), and 24% (6/25), respectively. The remission rate in the PD group
was signiﬁcantly better than that in the HD group (c2 ¼ 9.242,
p ¼ 0.002). The remission rate in the HDF group was also better
than that in the HD group (c2 ¼ 6.000, p ¼ 0.014). Although the
remission rate in the PD group was slightly better than that in the
HDF group, there was no signiﬁcant difference (c2 ¼ 0.306,
p ¼ 0.581). In the HD group, only two cases were signiﬁcantly
relieved of the pruritus symptoms and four cases were slightly
improved; by contrast, the pruritus symptoms were aggravated in
nine cases (Table 6).
4. Discussion
Pruritus is a common intolerable clinical symptom in elderly
uremic patients, with a clinical incidence of 50e90%10. Clinical
treatment requires multidisciplinary cooperation and incorporates
enhanced dialysis in combination with the use of oral or local an-
tipruritics, physical therapy, psychotherapy, music therapy, and
traditional Chinese medical treatments6,11e13. However, the efﬁcacy
of clinical treatment is usually poor.Table 5
Comparison of the pruritus scores.
Group Number
of cases
Before the
initial dialysis
After 8 wk
of dialysis
After 12 wk
of dialysis
HD 25 23.01 ± 3.58 21.95 ± 4.27 24.68 ± 4.39
HDF 20 20.98 ± 4.02 15.08 ± 3.56* 12.12 ± 2.98*
PD 22 22.15 ± 4.98 14.38 ± 4.01* 9.08 ± 3.55*
Data are presented as x ± s (points).
Comparedwith the same group before the ﬁrst dialysis, *p < 0.01; 12weeks after the
initial dialysis, compared with the HD group, *p < 0.01.
HD ¼ hemodialysis; HDF ¼ hemodiaﬁltration; PD ¼ peritoneal dialysis.
Table 6
Comparison of the effects of treatment on UP.
Group Cured
(%)
Signiﬁcantly
effective (%)
Effective
(%)
Ineffective
(%)
Pruritus remission
rate (%)
PD (n ¼ 22) 2 9 4 7 68.18*
HDF (n ¼ 20) 1 5 6 8 60.00**
HD (n ¼ 25) 0 2 4 19 24.00
Compared with the HD group, *p < 0.01, **p < 0.05.
HD¼ hemodialysis; HDF¼ hemodiaﬁltration; PD¼ peritoneal dialysis; UP¼ uremic
pruritus.
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recognized for many years, the precise pathophysiologic mecha-
nisms remain unclear. Narita et al4 showed that high levels of b2-
MG and iPTH were independently associated with the develop-
ment of severe UP. Recently, with a large number of evidence
accumulated in favor of the viewpoint that the uremia is an in-
ﬂammatory state, UP is considered as a skin counterpart of chronic
progressive inﬂammation in these patients14,15. Numerous studies
have suggested that iPTH and b2-MG are important components
that can cause inﬂammation in uremic patients4,5,16,17. Massry
et al16 suggested an outstanding role for secondary hyperparathy-
roidism and associated disorder of calcium and phosphorus meta-
bolism in the pathogenesis of UP. Zhang et al18 showed that T-cell
differentiation can be inhibited by high levels of iPTH, which may
decrease T-regulatory cells and increase inﬂammatory factors in
dialysis patients. It has been proved that the b2-MG content in skin
tissue increases with the duration of dialysis19, and b2-MG is a
major component of dialysis-associated amyloidosis20. Cutaneous
amyloidosis is one of the causes of xerosis, which is very prevalent
in end-stage renal disease patients21 and has been suggested as a
cause of UP3,22. Regardless of the mechanism of pruritus, the ﬁnal
common pathway appears to be the release of histamine frommast
cells. Neurophysiological factors are considered to play an impor-
tant role in UP23. iPTH and b2-MG may stimulate excessive pro-
duction of cytokines that may produce the pruritogenic
environment. We believe that the changes in the microenviron-
ment around the sensory nerve receptors play an important role in
UP development (Fig. 1).
HD has been in use for nearly 70 years with a rich background of
accumulated experience and is constantly improved. However, in
China and in other developing countries, low-ﬂux dialysis is still the
main method for toxin clearance, and it can hardly remove the
middle-molecule uremic toxins. The commonmiddlemolecules are
iPTH, b2-MG, and phosphorus, all of which are currently recognized
uremic toxins4,23. HDF not only can remove small molecule sub-
stances by diffusion, but can also remove middle-moleculeFig. 1. Working model for pathogenesis of iPTH or b2-MG with UP. iPTH or b2-MG may
accumulated locally and release pruritic mediators. 2 ¼ Histamine released from mast cel
cascade of signals from nerve endings activate speciﬁc areas in the central nervous system re
nerve endings release neuropeptides, which aggravate the pruritus response by stimulatin
thyroid hormone; UP ¼ uremic pruritus; b2-MG ¼ b2-microglobulin.substances by convection. It has previously been shown that pru-
ritus and bone painwere relieved following the application of HDF7.
Currently, many hospitals in China use a combination of HD þ HDF
to compensate for the deﬁciency of HD. PD incorporates the prin-
ciples of diffusion, convection, and ultraﬁltration, and can remove
small molecule toxins while partly removingmiddle-molecular and
macromolecular substances24,25. PD is gradually being accepted by
the majority of Chinese uremic patients in recent years26. iPTH is a
short-living peptide secreted by the parathyroid gland. Calcitriol
therapy can suppress iPTH levels. Nevertheless, dialysis seems to
have an inﬂuence on the iPTH levels directly as it is known that
iPTH levels decrease in the 1st year after starting dialysis24.
In this study, we applied three different dialysis modalities to
elderly uremic patients and found that the levels of b2-MG and
iPTH, and the scores of pruritus in the PD and HDF groups were all
signiﬁcantly decreased after 8 and 12 weeks of dialysis (all
p< 0.05); however, during the same period all these parameters did
not change signiﬁcantly in the HD group (all p > 0.05). After 12
weeks of dialysis, the pruritus remission rate in either the PD group
or the HDF groupwas signiﬁcantly better than that in the HD group.
The results of this study suggest that PD and HDF can partially
remove middle-molecule toxins such as serum b2-MG and iPTH in
uremic patients, and thus provide relief from pruritus; by contrast,
HD shows a worse performance with regard to middle-molecule
toxin clearance and pruritus relief.
5. Conclusion
For elderly uremic patients with signiﬁcant clinical symptoms
such as pruritus, PD or HDF treatment would be a better choice in
China and other developing countries, because low-ﬂux HD is not
so effective.
6. Limitations
The underlying mechanism for the occurrence of pruritus in
elderly uremic patients is complex; in addition to middle-molecule
toxins such as b2-MG and iPTH, pruritus can also be associatedwith
many factors such as anaphylatoxins, inﬂammatory mediators,
hyperphosphatemia, and immune disorders14,15,27, and therefore,
further in-depth studies are needed. Furthermore, this study had
certain limitations, For example, patient inclusion was not ran-
domized, the sample size was small, the observation time was
short, and only exclusively elderly uremic patients in a single
institution were studied with no younger control group, and
therefore, we cannot provide evidence for age-related difference on
the relief of pruritus. All of these factors will be continuously
optimized and improved in future studies.be proposed to produce the pruritogenic environment. 1 ¼ Inﬂammatory cells are
ls, in response to pruritogenic mediators, stimulates C-terminal nerve endings. 3 ¼ A
sulting in perception of pruritus. 4 ¼ Through a direct axon reﬂex mechanism, sensory
g the accumulated inﬂammatory cells, setting up a vicious circle. iPTH ¼ intact para-
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